David Stone 5/11/23 David Stone 5/11/23 BioNTech's Hesitance and Matinas BioPharma's Persistence: A Study in Risk Tolerance Read More Isha Tanaka 5/2/23 Isha Tanaka 5/2/23 Trojan Horse Drug Delivery: The Future of Medicine and Matinas BioPharma's LNC Technology Read More Mark Armstrong 5/1/23 Mark Armstrong 5/1/23 The Potential of Matinas BioPharma’s Lipid Nano-Crystal Technology in Drug Development Read More David Stone 4/24/23 David Stone 4/24/23 Is BioNTech About to Take a Major Stake in Matinas BioPharma? Read More Mark Armstrong 4/20/23 Mark Armstrong 4/20/23 Could the Next Pandemic Be Fungal-Based? Read More GripRoom Research 4/23/22 GripRoom Research 4/23/22 Matinas BioPharma - Insightful social media posts and due diligence Read More David Stone 3/19/22 David Stone 3/19/22 Growth Stocks are Back on the Menu as Fears of WW3 Fade Read More
David Stone 5/11/23 David Stone 5/11/23 BioNTech's Hesitance and Matinas BioPharma's Persistence: A Study in Risk Tolerance Read More
Isha Tanaka 5/2/23 Isha Tanaka 5/2/23 Trojan Horse Drug Delivery: The Future of Medicine and Matinas BioPharma's LNC Technology Read More
Mark Armstrong 5/1/23 Mark Armstrong 5/1/23 The Potential of Matinas BioPharma’s Lipid Nano-Crystal Technology in Drug Development Read More
David Stone 4/24/23 David Stone 4/24/23 Is BioNTech About to Take a Major Stake in Matinas BioPharma? Read More
GripRoom Research 4/23/22 GripRoom Research 4/23/22 Matinas BioPharma - Insightful social media posts and due diligence Read More
David Stone 3/19/22 David Stone 3/19/22 Growth Stocks are Back on the Menu as Fears of WW3 Fade Read More